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Abstract
The thymidine analog bromodeoxyuridine (BrdU) is incorporated into newly synthesized DNA and has been shown
to increase the susceptibility of incorporating cells to ionizing radiation. However, in the absence of secondary
stressors, BrdU is thought to substitute relatively benignly for thymidine and is commonly used to “birth-date”
proliferative cells. We report a novel antiproliferative effect of BrdU on cancer cells, which is independent of its
role in radiosensitization. A single, brief in vitro exposure to BrdU induces a profound and sustained reduction
in the proliferation rate of all cancer cells examined. Cells do not die but variably up-regulate some senescence-
associated proteins as they accumulate in the G1 phase of the cell cycle. Bromodeoxyuridine also impairs the pro-
liferative capacity of primary tumor–initiating human glioma cells and may therefore represent a means of targeting
cancer stem cells. Finally, conservative in vivo BrdU regimens—in the absence of any other treatment—significantly
suppress the progression of gliomas in the highly aggressive, syngeneic RG2 model. These results suggest that
BrdU may have an important role as an adjunctive therapeutic for a wide variety of cancers based on new insights
into its effect as a negative regulator of cell cycle progression.
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Introduction
5-Bromo-2′-deoxyuridine (BrdU) is a thymidine analog that was in-
troduced in the 1950s as a mutagen to target rapidly dividing cancer
cells [1–3] but is now used ubiquitously to birth-date dividing cells.
Although there are a myriad of reports dealing with the consequences
of BrdU incorporation into DNA chains [4–7], the variations in dos-
age and exposure time in these studies make it difficult to compare
individual results. Perhaps because of this, and because incorporating
cells seem to maintain relatively normal function—at least in the short
term [8]—BrdU is generally thought to substitute relatively benignly
for thymidine. Recent work, however, suggests that BrdU may play a
role in premature senescence induction in a wide variety of cells [9,10].
Despite its extensive history, there is no accepted consensus mecha-
nism of action for BrdU. It has been suggested that BrdU alters the
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stability of DNA, thereby increasing the risk of sister–chromatid ex-
changes, mutations, and double-strand breaks (reviewed in Taupin
[11]). However, most of these effects are found only when BrdU in-
corporation is combined with secondary stressors. Early toxicity studies
showed that BrdU can induce chromosomal breakage and increase the
sensitivity of treated cells to ionizing radiation [3,12,13], and this
radiosensitizing effect has continued to be pursued as an adjunctive
therapy in the treatment of a variety of cancers. Bromodeoxyuridine
readily crosses the blood–brain barrier, and it has been combined with
conventional chemotherapy and radiation treatment in several clinical
trials [14–19]. Although the clinical benefits of including BrdU as a
radiosensitizer have been disappointing—showing, at best, modest im-
provements for some outcome measurements—it is possible that other
therapeutic effects of BrdU were not appreciated, either because of in-
terference by the other treatment modalities in these studies or because
finer analytical resolution is required to discern them.
Surprisingly, little attention has been focused on examining the
influence that BrdU alone may exert on cellular function. In the pres-
ent study, we show that a single brief exposure to BrdU leads to a
progressive and sustained impairment of cell cycle progression in
all examined cancer cells in vitro. Treated cells do not die but grad-
ually accumulate in the G1 phase of the cell cycle while showing a
variable up-regulation of some senescence-associated proteins. Clonal
analysis of primary human glioma tumor cells with stem cell–like
characteristics shows that a single pulse of BrdU can impair the pro-
liferative capacity of the progeny of the putative tumor-initiating cells
over many population doublings. Therefore, BrdU may represent a
means of selectively targeting cancer stem cells. Most importantly, we
show that a brief oral or systemic regimen of BrdU leads to signifi-
cantly delayed tumor progression in a highly aggressive syngeneic rat
model of glioma.
Our results suggest that BrdU possesses therapeutic potential as an
anticancer agent that is independent of its role as a radiosensitizer
and that BrdU should be reassessed as an adjunctive therapeutic mo-
dality based on a new understanding of its antiproliferative effect.
Materials and Methods
Cell Culture
Cell lines were obtained from American Type Culture Collection
(http://www.atcc.org): H9, human cutaneous T-cell lymphoma
(#HTB-176); MG-63, human osteosarcoma (#CRL-1427); Saos-2,
human osteosarcoma (#HTB-85); TT, human thyroid tumor (#CRL-
1803); BJ, human fibroblasts (#CRL-2522); and RG2, rat glioma
(#CRL-2433). Primary human glioma cells were generated from a sur-
gical resection. Experiments were performed in triplicate cultures main-
tained in a 37°C humidified chamber containing 5% CO2.
In Vitro Drug Treatment and Quantification of
Proliferative Activity
All reagents were purchased from Sigma (St. Louis, MO) unless
otherwise noted: BrdU (#B9285), BrdU (#B23151 from Molecular
Probes, Eugene, OR), 5-chloro-2′-deoxyuridine (CldU; #C6891),
5-iodo-2′-deoxyuridine (IdU; #I7125), 5-aza-2′-deoxycytidine (AZA;
#A3656), 5-fluorouracil (5-FU; #F6627), thymidine (#T1895),
and cytidine (#C4654). Exposure times ranged from 1 minute to
24 hours, after which the medium was aspirated and replaced with
fresh medium without analogs. Control and treated cultures received
the same number of medium changes.
Cultures were initially plated at 2000 cells/cm2 and were quanti-
fied with a Z2 Coulter Counter (Beckman Coulter, Fullerton, CA) at
various intervals after the removal of BrdU (range = 1 minute to sev-
eral weeks).
Neurosphere cultures of primary human glioma cells were estab-
lished and maintained as described [20].
Statistical Analyses
All analyses were performed with GraphPad InStat and Prism 4
(San Diego, CA). Two-group comparisons of cell counts were per-
formed with the Student’s t test. Multiple-group comparisons were
performed with either a one-way or two-way analysis of variance
(ANOVA). Tumor progression data is expressed as Kaplan–Meier
survival curves.
For the compound statistical model (Figure 2A; Table W1), the
ratio was estimated using mean (exp group)/mean (control group)
for each cancer line/time point combination. The SD was computed
according to Cochran’s equation 6.4 [21]. Under the null hypothesis
that the ratio is 1, the test statistic is a z-statistic, which has the stan-
dard normal distribution if the null is true. An asterisk (*) indicates
significance using the Bonferroni correction for multiple tests.
Immunolabeling
Cells were processed for BrdU immunolabeling as previously de-
scribed [22]. Briefly, cells were incubated for 2 hours in a 1:1 ratio
of 2× SSC/formamide at 65°C. After a wash in 2× SSC, the cells
were then incubated for 30 minutes at 37°C in 2N HCl. Finally,
the cells were equilibrated at room temperature for 10 minutes in
borate buffer, followed by standard indirect immunofluorescence de-
tection of BrdU with a rat anti-BrdU antibody (#ab6326; Abcam,
Cambridge, MA).
For cleaved caspase-3 and γH2A.X immunolabeling, cells were
grown to ∼75% confluence on polyornithine-coated glass coverslips.
The medium was removed, and the cells were fixed by incubating in
4% paraformaldehyde in PBS at room temperature for 15 minutes
then washed with PBS for 5 minutes. Cells were prepared for immuno-
cytochemistry by first blocking at room temperature for 1 hour in
PBS plus 0.01% Triton X-100 (PBSt) containing 10% fetal bovine
serum (FBS). Primary antibodies were then applied to the cells for
1 hour in PBSt plus 10% FBS with moderate agitation at 37°C.
The antibodies used were either cleaved caspase-3 (at 1:400, #9661S;
Cell Signaling Technology, Danvers, MA) or γH2A.X phospho-S139
(at 1:200, #ab2893; Abcam). Residual primary antibody was removed
by three 5-minute washes with PBS, and secondary antibodies were ap-
plied at room temperature for 1 hour in PBSt plus 10% FBS. Residual
secondary antibodies were removed by three 5-minute washes in PBS.
The coverslips were placed onto glass slides and Vectashield mounting
medium plus DAPI (H-1200; Vector Laboratories, Burlingame, CA)
was applied immediately before coverslipping.
Flow Cytometry
Cell cycle analysis (propidium iodide). Cells were fixed overnight
in 70% ethanol and then incubated for 1 hour at 4°C in PBS con-
taining 50 μg/ml of propidium iodide (#P-4170; Sigma-Aldrich)
and RNase A (#R6513; Sigma-Aldrich). Samples were processed
with a FACSCalibur flow cytometer (BD Biosciences, San Jose,
CA). Data were analyzed with FlowJo Flow Cytometry Analysis Soft-
ware (Tree Star, Inc., Ashland, OR).
Neoplasia Vol. 10, No. 8, 2008 BrdU Inhibits Cancer Cell Proliferation Levkoff et al. 805
Annexin V. Cells were harvested at various time points after BrdU
administration (50 μM) to assess Annexin V staining using the Vybrant
Apoptosis Assay Kit #9 (V35113; Molecular Probes, Carlsbad, CA).
Briefly, cell pellets were obtained by centrifugation and resuspended
at 1 × 106 cells/ml in 1× annexin binding buffer (ABB). Annexin V
(APC) and SYTOX green stain were added to the cell suspension and
incubated with 5% CO2 for 15 minutes at 37°C. The cell suspension
was diluted with 1× ABB, gently mixed, and analyzed by flow cytometry
(530/660 nm). Populations were separated based on high and low levels
of red and green fluorescence.
JC-1. We performed the JC-1 assay to determine whether BrdU
exposure causes any changes in mitochondrial membrane potential.
Control and BrdU-treated cells were suspended in warm medium
at 1 × 106 cells/ml. The positive control sample was treated with
CCCP and incubated at 37°C for 5 minutes. All groups received
2 μM JC-1 and were incubated at 37°C, 5% CO2 for 30 minutes.
Cells were washed once and resuspended in 500 μl of PBS. Samples
were then analyzed on a flow cytometer with 488-nm excitation
using the appropriate emission filter for Alexa Fluor 488 dye and
R-phycoerythrin. Cells were gated to exclude debris, and standard
compensation was performed using the CCCP-treated sample.
Western Blot Analysis and Densitometry
Proteins were isolated from adherent cell lines (RG2 and BJ) by in-
cubating with RIPA extraction buffer (50 mM Tris–HCl, 150 mM
NaCl, 1%NP-40, 1% sodium deoxycholate, and 1% sodium dodecyl
sulfate) containing protease inhibitor cocktail (Calbiochem, San Diego,
CA) on flasks over an ice bath for 5 minutes followed by cell scraping.
Extracted protein was quantified against a bovine serum albumin stan-
dard using a DC protein assay reagent kit (Bio-Rad, Hercules, CA).
Equal protein was loaded onto Bis–Tris 4% to 12% density gradi-
ent gels, and electrophoresis was performed using NuPAGE MES
[12(N -morpholino) ethane sulfonic acid] reducing buffer system
(Invitrogen, Carlsbad, CA) for 50 minutes at 200 V. Proteins were
transferred onto nitrocellulose membranes for 1 to 1.5 hours at 30 V.
Nonspecific binding was blocked with 5% bovine milk in Tris-buffered
saline plus 0.05% Tween 20. Membranes were incubated in a blocking
buffer at room temperature for 1 hour before being probed with the
following primary antibodies: phosphospecific (Ser249,Thr252) antiret-
inoblastoma (at 1:500, PC640; Oncogene Research Products, San
Diego, CA), p21 (at 1:500, #ab7960; Abcam), antihuman retinoblas-
toma protein (1:200, #554136; BD Pharmingen, San Jose, CA), and
antiactin (at 1:2000, A-4700; Sigma). Membranes were incubated in
primary antibody at 4°C overnight and then probed with an appro-
priate secondary antibody for 1 hour at room temperature. Finally,
immunopositive proteins were detected by autoradiography using
ECL reagents (GE Healthcare Life Sciences, UK), and densitometry
was quantified with Image J software.
Subcutaneous Tumors and In Vivo BrdU Administration
A bolus of either untreated or pretreated RG2 glioma cells (1 ×
106 cells in 250 μl of PBS) was injected subcutaneously between
the scapulae of anesthetized adult male Fisher 344 rats as previously
described [23]. Pretreated RG2 cells were treated with 50 μM BrdU
for 24 hours before implantation. Tumors were measured every other
day in two dimensions with digital calipers, and tumor volume was
calculated [(π/6) × W 2 × L (W = shortest dimension and L = longest
dimension)]. The experimental end point was defined as a tumor vol-
ume ≥3000 mm3. At end point, euthanasia was performed by trans-
cardial perfusion with 200 ml of 4% paraformaldehyde in PBS under
deep sodium pentobarbital anesthesia (150 mg/kg, i.p.).
BrdU administration, i.p. Untreated RG2 cells were implanted
into 10 animals as described previously. The BrdU regimen was ini-
tiated when palpable tumors had reached a volume of 200 mm3. Half
of the animals received three i.p. injections of BrdU (300 mg/kg) per
day for 2 days, whereas the other half served as controls and received
an equal number and volume of sterile saline injections.
BrdU administration, oral. Again, untreated RG2 cells were im-
planted subcutaneously into 20 animals as described. Immediately
after implantation, half of the animals were provided with drinking
water containing BrdU (0.8 mg/ml), and half received normal drink-
ing water. All animals were provided with freshly prepared water
(either with or without BrdU) each day for 7 days, ad libitum. On
the eighth day after implantation, all animals were placed on normal
drinking water for the duration of the experiment.
A dose of 300 mg/kg corresponds to a clinical dose of 1800 mg/m2.
The rats received three of these doses per day for 2 days, thus receiv-
ing a total of 10,800 mg/m2. The drinking water dose (based on
the standard 20-ml/day consumption by adult rats) is 640 mg/m2
per day for 7 days, or a total of 4480 mg/m2. By way of comparison,
previous clinical trials (e.g., Kinsella et al. [14]) included BrdU as a
radiosensitizer as part of a multimodal therapy–treated patients with
350 mg/m2 for continuous 12-hour infusions every day for 14 days
or 4900 mg/m2 total. Thus, the treatment range in our study is gen-
erally in accord with previous human clinical applications, because,
although our injected BrdU was theoretically approximately twice
what humans received, it is known that BrdU is active in plasma only
for approximately 2 hours. Therefore, the continuous infusion used
in the human trials likely resulted in more widespread BrdU incorpo-
ration than our injection paradigm.
Terminal Deoxynucleotidyl Transferase–Mediated dUTP
Nick-End Labeling
Apoptotic cells from control and BrdU-treated cultures were visual-
ized using a fluorimetric terminal deoxynucleotidyl transferase–mediated
dUTP nick-end labeling (TUNEL) assay (DeadEnd Fluoremetric
TUNEL System G3250; Promega, Madison, WI) according to the
manufacturer’s recommendations. This assay measures the fragmented
DNA of apoptotic cells by incorporating fluorescein-labeled dUTP at
the 3′ ends of DNA strands. As a positive control, some cells were pro-
cessed for TUNEL after 30 minutes of incubation with DNase. Cells
were counterstained with Vectashield + DAPI (H-1200; Vector Labo-
ratories), and cell death was quantified by counting the number of
TUNEL+ nuclei on each of three coverslips at five predetermined stage
coordinates. The criterion for apoptotic cells was intentionally liberal
to avoid undercounting (i.e., nuclei with even the faintest evidence of
fluorescein label were considered positive).
Telomere Length
To determine whether the effects of BrdU are related to changes in
telomere length, we performed a TeloTAGGG assay (catalog no.
2209136; Roche, Indianapolis, IN). Briefly, genomic DNA was iso-
lated (#11814770001; Roche) and digested with Hinf1 and Rsa1
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enzymes. After digestion, the DNA fragments were separated by gel
electrophoresis and transferred to a nylon membrane for Southern
blot analysis. The blotted DNA fragments were hybridized to a di-
goxigenin (DIG)-labeled probe specific for telomeric repeats and in-
cubated with a DIG-specific antibody covalently coupled to alkaline
phosphatase. Finally, the immobilized telomere probe was visualized
by virtue of alkaline phosphatase–metabolizing CDP-Star, a highly
sensitive chemiluminescence substrate.
Telomerase Activity
Weused the TRAPeze ELISA kit (#S7750;Chemicon,Danvers,MA)
assay to determine levels of telomerase activity in our control and
BrdU-treated cells. Briefly, the sample cells’ telomerase adds a number
of telomeric repeats (GGTTAG) onto the 3′ end of the biotinylated
telomerase substrate oligonucleotide (b-TS), and the extended prod-
ucts are then amplified by polymerase chain reaction. The extension/
amplification was performedwith biotinylated primer andDNP-labeled
dCTP. Thus, the telomeric repeat amplification protocol (TRAP) prod-
ucts are tagged with biotin and DNP residues, and the labeled products
can be immobilized onto streptavidin-coated microtiter plates through
biotin–streptavidin interaction, and then detected by anti-DNP anti-
body conjugated to horseradish peroxidase (HRP). The amount of
TRAP products was determined by means of the HRP activity using
substrate TMB and subsequent color development.
Results
BrdU Administration Reduces Cancer Cell Population
Expansion Over Time
RG2 rat glioma cells were treated once with 0, 1, 10, or 50 μM
BrdU for 24 hours, and cumulative growth curves were obtained over
18 days (Figure 1A). Control and treated cells were quantified and
replated at equal densities on days 5, 12, and 18 after treatment. At
all time points, the BrdU-treated cells demonstrate a statistically sig-
nificant dose-responsive decrease in cell numbers, which becomes
more pronounced with increasing rounds of replication (data are ex-
pressed as population doublings over time, and statistical analysis was
performed on total cell counts). To more finely analyze the temporal
effect of BrdU on cell number, we repeated this experiment with non-
adherent H9 human lymphoma cells, quantifying at 1, 2, or 4 days
after exposure (Figure 1B). These results show that there is a delay
of approximately 48 hours before statistically significant differences
in cell number are detected. Most cell lines examined fail to display
any sign of recovery. However, when we followed H9 cells that were
treated for 24 hours with 50 μM BrdU and quantified periodically
over 2 months, we found the initial dramatic reduction in the rate of
proliferation was followed by a gradual recovery to near normal levels
over the course of 61 population doublings (data not shown).
We next examined the effect of BrdU administration on primary
cancer cells with stemlike properties using the neurosphere (NS) assay
[24,25]. Neurospheres are clonal structures consisting of progeny de-
rived from a single founder cell capable of long-term self-renewal and
multilineage differentiation [26]. Neural stem–like cells capable of
forming NS are present in primary gliomas [27] and represent tumor-
initiating cells in serial transplantation paradigms [20,28]. Neuro-
spheres derived from primary human gliomas and treated with a single
pulse of either 5 or 10 μM BrdU show a dose-dependent reduction in
the rate of population doubling compared to untreated control cells
(Figure 1C ).
Figure 1. BrdU induces a progressive, dose-responsive suppres-
sion of cancer cell line and cancer stem cell population expansion.
(A) RG2 rat glioma cells treated for 24 hours with 1, 10, or 50 μM
BrdU show a dose-responsive reduction in the rate of population
doubling over 18 days after removal of BrdU. Cells from all groups
were replated at equal density at 120 and 288 hours to prevent
overgrowth of the culture vessels. At all time points, BrdU-treated
cells lag significantly behind controls, regardless of dose (one-way
ANOVA, Tukey–Kramer post hoc test of significancewas performed
on the basis of total cell counts at each time point; P< .001, n = 3
for all groups). (B) Finer temporal analysis reveals that significantly
slowed expansion is apparent as early as 48 hours after BrdU. H9
human lymphoma cells treated for 24 hours with 1, 5, 10, or 50 μM
BrdU are not significantly different from control at 24 hours after
BrdU exposure, yet by 48 hours, all treated groups lag significantly
behind control, and the degree of lag is dose-responsive (one-way
ANOVA, Bonferroni post hoc test of significance; P< .001, n=3 for
all groups). (C) Tumor-initiating cancer stem cells isolated from
a primary human glioma were treated with a single pulse of 5 or
10 μM BrdU and grown in NS cultures. Neurospheres were pas-
saged, quantified, and replated every 4 to 7 days. Both doses
severely suppress cancer stem cell population expansion. Data
are represented as mean ± SD.
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The inhibitory effect of BrdU on proliferation is common to all
mammalian cells that we have tested. Figure 2A is a graphical repre-
sentation of BrdU-induced reduction in expansion rate for a number
of cell lines (Table W1 for statistical results). Expansion is expressed
as percent of control, and all treated cells show a dramatic, sustained,
and statistically significant reduction in the rate of expansion com-
pared to matched, untreated controls. Because our paradigm includes
only a single pulse of BrdU, and because treated cells are affected for
numerous population doublings, we reasoned that impaired prolifera-
tion, while requiring initial BrdU incorporation into cellular DNA,
is maintained even as the amount of retained BrdU decreases due to
dilution with each round of cell division. We exposed MG63 human
osteosarcoma cells to 50 μM BrdU for 18 hours and assessed BrdU
immunolabeling over 2 weeks. At 24 hours after treatment, greater
than 95% of cells are BrdU+, and the labeling is characteristically
spread over the entire nucleus (Figure 2B). By day 6 (Figure 2C ), most
cells are still decorated, but the pattern is patchy and less intense. On
day 11 (Figure 2D), only approximately half of all cells still express
immunodetectable amounts of BrdU, and the patchy pattern is more
pronounced. Finally, by day 13 (Figure 2E ), only occasional cells are
labeled, and these typically show only a single focal point within the
nucleus. At later times, nuclear BrdU is not detected (data not shown).
These data demonstrate that proliferation suppression does not de-
pend on the continued presence of BrdU within the DNA.
Single-Pulse BrdU Does Not Result in Increased
DNA Damage or Apoptosis
Reports associating BrdU with DNA damage generally involve the
use of a secondary stressor such as irradiation, rendering it difficult to
discern whether BrdU alone has an effect. It is plausible that BrdU
exposure induces DNA damage that can cause stress in other cellular
components, leading to amplification of apoptosis [29]. We labeled
control and BrdU-treated cells with γH2A.X at various time points
after BrdU administration to determine whether DNA damage, spe-
cifically double-strand breaks, is induced. We found with BJ and
MG63 cells that there are no consistent differences in the number
of γH2A.X-positive cells between treated and control groups during
the first 4 days after exposure to BrdU. At no time did the percentage
of positive cells in either control or treated groups exceed 2% of the
total population, and in some instances, the percentage was higher in
the controls (Figure 3). Next, we examined increased BrdU-mediated
sensitivity to photolysis, as described by Michishita et al. [30]. Treated
cells that were protected from ambient light for 5 days still show pro-
found expansion suppression, demonstrating that DNA damage due
to irradiation does not account for the observed effect (Figure W1).
To assess BrdU-mediated apoptosis, we examined cells with the
TUNEL assay that detects DNA fragmentation characteristic of ap-
optotic cells. As with the γH2A.X labeling, we found only negligible
increases in TUNEL+-treated cells (Figure W2A) that cannot account
for the profound reduction in expansion rate, because TUNEL+
cells never accounted for more than 0.5% of the total population.
Because the TUNEL assay predominately detects late-stage apopto-
sis, we also assessed cells for mitochondrial membrane potential,
cleaved caspase-3, and Annexin-V staining, which all detect early
apoptotic events.
An early event in apoptosis is the collapse of the electrochemical
gradient across the mitochondrial membrane, and the measurement
of mitochondrial membrane potential is a method to detect apopto-
sis. We compared the mitochondrial membrane potential of treated
and control MG63 cells at 1 and 7 days after a 24-hour pulse of
50-μM BrdU. These results (Figure W3) fail to reveal differences
in mitochondrial membrane potential between control and BrdU-
treated cells.
Activation of cleaved caspase-3 is another early event in cellular ap-
optosis. We examined BJ and MG63 cells for caspase-3 expression
over 4 days after a 24-hour pulse of BrdU (Figure W2B). As with
the TUNEL results, the percentage of cells expressing caspase in all
groups was very low, never exceeding 1% of the total. Additionally,
there were no consistent differences between treated cells and matched
controls in either group. Thus, three methods for detecting apoptosis
indicated that the level of cell death in BrdU-treated cultures is very
low and not significantly different from the control level.
Finally, we examined Annexin V binding that reveals the loss of
plasma membrane asymmetry that allows phosphatidylserine, nor-
mally located in the inner layer, to be exposed on the cell surface.
Such loss of asymmetry is thought to be associated with cells that will
Figure 2. Proliferation suppression is common among all cancer
cells examined and is independent of BrdU retention. (A) Our stan-
dard treatment paradigm of 50 μM BrdU for 24 hours causes a
reliable suppression of expansion in various cell lines. The top panel
shows the graphical representation of expansion by BrdU-treated
cells (shown as percent control) over a range of 0 to 14 population
doublings after removal of BrdU (see statistical analysis of thismodel
in Table W1). MG63 human osteosarcoma cells were exposed to a
single, 18-hour pulse of 50 μMBrdUand assessed over time for BrdU
retention. At 24 hours after exposure (B), greater than 95%of all cells
show substantial BrdU immunoreactivity (green) within the nucleus.
The amount and intensity of BrdU label progressively declines at 6
(C), 11 (D), and 13 (E) days after exposure. Cell nuclei are counter-
stained with propidium iodide (red). Scale bar in (C), 20 μm and ap-
plies to all panels.
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eventually execute an apoptotic program. H9, Saos-2, and BJ cells
were examined after a single 24-hour exposure to BrdU (50 μM).
In addition, a dose–response study was carried out with MG63 cells.
The results with Annexin V are highly variable and somewhat confus-
ing (Figure W2, C and D). There is a dose-responsive increase in the
percentage of cells labeled with Annexin V, with greater than 60% of
all cells either dead or Annexin V(+) after exposure to 50 μM BrdU
for 24 hours. The results with the other cell lines are highly variable.
Treated H9 cells seem to show a slight increase in the Annexin V(+)
population, whereas there is no increase in treated Saos-2 cells. BJ cells
also fail to reveal differences in Annexin V levels between treated and
control groups, but the base level of expression is approximately 50%
even in the untreated controls. Because the Annexin V results are so
dramatically different from the results obtained with other markers of
apoptosis, and because there is large intra–cell line variability in both
baseline Annexin V expression and degree of change after BrdU expo-
sure, we believe that these results do not accurately reflect cell death in
our culture paradigm. This is supported by reports in the literature
demonstrating that Annexin V labeling can sometimes be reversible
[31] and that Annexin V labeling can increase even without eventual
cell death [32].
Antiproliferation Follows Even Low-Dose
BrdU Administration
To determine the lowest effective dose of BrdU for slowing expan-
sion, we treated RG2 cells with 0.01, 0.1, 1.0, or 10 μM BrdU for
18 hours and quantified after 8 days. A dose–response is again appar-
ent, with 10 μM eliciting a stronger effect than 1.0 μM. However,
doses lower than 1.0 μM fail to alter expansion (Figure 4A). Identical
results were also obtained with BJ cells (data not shown). Anti-BrdU
labeling reveals that only doses of 1 μM or higher result in immuno-
detectable levels of BrdU within the cell nuclei. At 24 hours after
treatment, BrdU is seen in more than 95% of BJ cells treated with
1.0 or 10 μM BrdU, whereas cells treated with 0.1 μM BrdU or
lower fail to demonstrate any immunolabeling (Figure 4B). This
finding demonstrates that BrdU must incorporate into cellular
DNA at immunodetectable levels to elicit the antiproliferation effect.
BrdU Alters the Cell Cycle Profile
Because BrdU leads to a reduced cellular expansion over time that
is not the result of increased cell death, we hypothesize that there
must be an alteration in the cell cycle profile of treated cells. We treated
asynchronous BJ fibroblasts with 50 μM BrdU for 24 hours and
Figure 3. BrdU does not lead to increased γH2A.X immunoreactivity. (A) BrdU-treated (B) and matched control (C ) BJ or MG63 cells
immunostained for γH2A.X at 1, 6, 24, 72, and 96 hours after a single 24-hour pulse of BrdU, and positive cells are expressed as the
percentage of the total cell population. Although there is a trend toward greater γH2A.X expression in both control and treated cells with
increasing time in culture, there are no consistent differences between matched control and treated samples in either cell type. (B)
Representative photomicrographs showing examples of γH2A.X(+) and γH2A.X(−) MG63 cells 96 hours after a single 24-hour pulse
of 50 μM BrdU. The panel on the left shows DAPI staining of two nuclei (pseudocolored magenta). The middle panel shows γH2AX
immunolabeling (green) of the same field of view. The right-hand panel is an overlay of two panels. Characteristic γH2AX(+) foci are
present in the upper nucleus, indicating double-strand DNA breaks. Scale bar, 10 μm.
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compared their cell cycle profile to control cells after 1 week. As ex-
pected, there is a statistically significant reduction in the proportion
of BrdU treated cells in S-phase that is offset by an increase in the frac-
tion of treated cells in G0/G1 (Figure 5). Finer analysis with similarly
treated RG2 cells reveals that, as early as 6 hours after BrdU adminis-
tration, there is a statistically significant reduction in the proportion of
cells in S-phase in treated groups. The ratio of treated to control cells in
S-phase varies, but at all times over 1 week after exposure, there are
fewer BrdU-treated cells in S-phase. H9 cells treated for 24 hours with
50 μM BrdU also show a reduction in the proportion of cells in
S-phase by 24 hours after BrdU exposure, and this reduction remains
relatively stable over the next 2 days (data not shown). These findings
demonstrate that BrdU exposure leads to a rapid alteration in cell cycle
distribution that precedes a detectable delay in expansion rate as mea-
sured by total cell quantification.
The increase in the population of BrdU-treated cells in G1 sug-
gests the possibility that these cells are either exiting the cell cycle
or are unable to traverse the restriction point. The control of cellular
proliferation is tightly regulated by various intrinsic and extrinsic
factors. However, the retinoblastoma protein (pRb) is recognized as
a guardian of the restriction point and cell cycle progress [33]. To
test the effect of BrdU on pRb phosphorylation, RG2 and BJ cells
were administered BrdU (50 μM) at 0 hours, and cell lysates were
collected at various postadministration time points (1, 6, and 96 hours
and 7 days) for Western blot analysis. At 24 hours, the BrdU-
containing medium in the 96-hour and 7-day culture flasks was re-
placed with BrdU-free medium. The level of phosphorylated pRb in
BrdU-treated RG2 cells is negligible at 6 hours after administration,
and there is no detectable expression at 96 hours or at 7 days (Figure 6,
A and C). Additionally, phosphorylated pRb expression is no longer
detectable in BrdU-treated BJ cells by 96 hours after administration
(Figure 6, B and D). The time at which the level of phosphorylated
pRb declines corresponds with the G1 accumulation (Figure 5). The
decrease in expression level seems to be phosphorylation-specific be-
cause the levels of total pRb are comparable between control and
BrdU-treated cells, particularly in the BJ cells, at these time points
(Figure 6, E and F ).
Most of the cell lines we use have abnormal expression patterns
for many of the primary markers related to G1 arrest (Table W2),
making it difficult to assign the effect of BrdU to any of the prom-
inent cell cycle and/or senescence pathways. However, the expres-
sion profile of a key cell cycle protein, p21, has been reported as
normal in both the RG2 and BJ cell lines. Interestingly, the level
of p21 does not change after BrdU treatment (Figure 6, E and F ).
This result is not necessarily surprising when one considers the fact
that both H9 and Saos-2 cells do not express p21 yet are still sensitive
to BrdU treatment.
The slowed expansion and altered cell cycle profile of BrdU-treated
cells resembles a senescent-like phenotype, and there is evidence
that halogenated pyrimidines can induce senescence in a variety
of cell types [9,10,29,34]. However, the expression levels of known
senescence-associated proteins are not consistently altered by BrdU
exposure. For instance, senescence-associated β-galactosidase (SAβ-
gal) activity [35] is up-regulated in RG2 cells 24 hours after exposure
to 10 μM BrdU (Figure W4). In contrast, there is no detectable SAβ-
gal activity in severely suppressed MG63 cells (data not shown). Simi-
lar ambiguous results were obtained in relation to telomerase activity
and telomere maintenance. Telomere erosion during cellular repli-
cation has been shown to activate DNA damage signaling pathways
that can inhibit subsequent cell cycle progression and induce senes-
cence [36]. To examine BrdU-mediated perturbation of telomerase ac-
tivity as a mechanism of slowed cell cycle progression, we performed
TRAP analysis on control and BrdU-treated RG2 cells. Telomeric re-
peat amplification protocol analysis performed 24 and 48 hours after
treatment reveals strongly reduced telomerase activity (Figure W5A).
Again, however, this reduction is variable and cell line–specific because
MG63 cells fail to demonstrate a reduction in telomerase activity, even
3 weeks after exposure (data not shown). Furthermore, the telomerase-
negative BJ and Saos-2 cell lines also demonstrate BrdU-mediated
proliferation suppression (Figure 2), suggesting that telomerase activ-
ity is not directly involved in BrdU-mediated antiproliferation but
may itself be reduced in telomerase-positive cells subsequent to cell
cycle alterations.
Under some circumstances, telomeres can be maintained by a
telomerase-independent mechanism referred to as alternative length-
ening of telomeres [37]. Because telomere length can be maintained
in the absence of telomerase activity, and because BrdU induces slowed
proliferation in cells regardless of telomerase activity, we looked for evi-
dence of telomere shortening through terminal restriction fragment
analysis in H9 cells but failed to detect differences in average telomere
length between treated and control cells (Figure W5B).
The relationship between cellular metabolism and cell cycle con-
trol is not well understood. However, it has been reported that energy
Figure 4. Transient, low-dose BrdU suppresses expansion rate. (A)
RG2 cells were treated with a single 18-hour pulse of 0.01, 0.1, 1.0,
or 10 μM BrdU and were quantified 8 days later. Cells receiving a
0.01 or 0.1 μM dose were not significantly different from control
at 8 days, whereas expansion of both the 1.0 and 10 μM groups
was significantly suppressed (one-way ANOVAwith a Tukey–Kramer
post hoc test of significance; P < .001. n = 3 for each group.). (B)
BrdU doses that fail to suppress expansion also fail to immuno-
label treated cells. Both the 1 and 10 μM groups demonstrate BrdU
immunolabeling (green) of nearly all cells 24 hours after BrdU expo-
sure, whereas the 0.1 μM group does not contain immunodetect-
able BrdU. Scale bar, 20 μm. Data are represented as mean ± SD.
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Figure 5. BrdU alters the cell cycle profile. Cell cycle kinetics of asynchronous control and treated cells were assessed using flow cy-
tometry (propidium iodide staining) after a 24-hour pulse of 50 μMBrdU. At 144 hours after exposure, treated BJ cells (pie charts) show a
substantial increase in the percentage of cells in G1/G2 with a corresponding reduction in S-phase. The table on the right shows the
results of finer temporal analysis with H9 and RG2 cells. Even as early as 6 hours after BrdU exposure, there is a reduction in the per-
centage of cells in S-phase that persists over time.
Figure 6. Phosphorylation of pRb is reduced in some cell types after BrdU exposure, whereas total pRb and p21 remain unchanged. (A
and B) RG2 and BJ cells were exposed to a single 24-hour pulse of 50 μM BrdU and analyzed for phosphorylated pRb (Ser249,Thr252) by
Western blot analysis at 1, 6, and 96 hours and 7 days after administration. (C and D) Densitometric analysis was performed to quan-
titate the changes in phosphorylated pRb protein levels in RG2 and BJ samples normalized to actin. There is a dramatic reduction in
phospho-Rb beginning at 6 hours in the RG2 cells, and at 96 hours in the BJ cells. (E and F) Similarly treated RG2 and BJ cells were
analyzed for total Rb, and p21 protein expression by Western blot analysis. Total Rb decreases slightly in RG2 cells at 1 week after
administration but is not altered in BJ cells. In neither cell type is p21 expression altered because of BrdU exposure. (Amount of protein
loaded/well: (A and B) RG2 1 hour, 6 hours: 17 μg; RG2 96 hours, 7 days: 20 μg; BJ 1 hour, 6 hours: 15 μg; BJ 96 hours: 17 μg; (C and D)
RG2: 15 μg; BJ: 17 μg.)
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deprivation can prevent passage through the G1–S cell cycle check-
point [38]. Whereas BrdU can incorporate into mitochondrial DNA
[39], little is known about how it affects mitochondrial health and/or
function. Mitochondrial membrane potential is a key indicator of cel-
lular viability and is critical for ATP production. As we have already
shown (Figure W2), BrdU does not lead to perturbed mitochondrial
membrane potential either 1 day or 1 week after treatment. Identical
results were obtained with both H9 and BJ cells (data not shown).
BrdU-Mediated Antiproliferation Is Not Blocked by the
Addition of Cytosine or Thymidine
While BrdU normally pairs with adenosine during DNA replica-
tion, it is also known to frequently mispair with guanine [40–45].
Bromodeoxyuridine triphosphate (BrdUTP) is an inhibitor of ribo-
nucleoside diphosphate reductase, which ultimately leads to a defi-
ciency in the conversion of cytidine diphosphate to deoxycytidine
diphosphate [40,42]. High BrdUTP concentrations, therefore, may
prevent the formation of dCTP substrate for DNA synthesis. With a
decrease in dCTP pools, BrdUTP becomes increasingly competitive
for sites opposite template guanines, an effect that can be mitigated
by the addition of excess deoxycytidine [45].
We followed the expansion rates of H9 cells treated with equimo-
lar BrdU, thymidine, or cytidine, both alone and in combination
(Figure 7A). The reduced cellular expansion produced by 50 μM
BrdU is abrogated neither by the coadministration of equimolar thy-
midine or cytidine nor by a combination of thymidine and cytidine.
Furthermore, neither thymidine nor cytidine, alone or in combina-
tion, significantly reduces proliferation rate compared to untreated
controls cells. Finally, the antiproliferative effect of 50 μM BrdU is
not diminished even when coadministered with up to 250 μM cyti-
dine (data not shown). These results suggest that antiproliferation
arises neither from BrdU outcompeting cytidine during DNA syn-
thesis nor by simply altering the intracellular milieu by the addition
of excess nucleotides.
Halogenated Pyrimidines Suppress Proliferation More Robustly
Than Current Anticancer Nucleosides
To determine whether halogenated pyrimidines structurally similar
to BrdU also perturb proliferation, we analyzed the effect of CldU
and IdU on H9 cell expansion weekly for three consecutive weeks
after an 18-hour exposure to 1, 10, or 50 μM of each thymidine
Figure 7. BrdU-mediated proliferation suppression is not antago-
nized by excess cytidine, is matched by similar halogenated pyrimi-
dines, and surpasses current anticancer nucleoside analogs. (A)
50 μMBrdU, deoxycytidine (dCyd), and deoxythymidine (dThy) were
applied to H9 human lymphoma cells in factorial combinations for
24 hours, and cellular expansion was assessed 1 week later. All of
the groups receiving BrdU showed statistically indistinguishable re-
ductions in expansion compared to control (P < .001). In contrast,
groups receiving dCyd, dThy, or dCyd+dThy demonstrated expan-
sion equivalent to control levels. One-way ANOVA with a Tukey–
Kramer post hoc test of significance. n = 3 for each group. Error
bars represent SD. (B) BrdU (B), CldU (C ), and IdU (I ) were compared
for the ability to suppress expansion of H9 human lymphoma cells.
Each analog was administered for 18 hours at 1, 10, or 50 μM and
cells were quantified weekly for 3 weeks (weekly counts corre-
spond to a left-to-right progression of color-coded triplicates of
bars). At all doses and time points, the three halogenated pyrimi-
dines produce remarkably similar, statistically significant reduc-
tions in cell number compared to untreated controls. (C) In the
same experiment, the therapeutic anticancer nucleoside analogs
5-fluorouracil (FU) and 5-azacytidine (A) were also examined for
their ability to suppress expansion of H9 cells in the same paradigm.
Approximately 50 μMFU is slightly more effective than 50 μMBrdU
at week 1, but by week 2, 50 μMBrdU is substantially better at sup-
pressing expansion. At week 3, 50 μM BrdU suppression has not
changed, whereas 50 μM FU suppression has started to recover
toward control. At all other doses and time points BrdU is as effec-
tive as or more effective than FU at suppressing expansion, and
BrdU suppression persists longer. 5-Azacytidine shows variable
and transient suppression of expansion to near 80% of control lev-
els. Counts were analyzed with a two-way ANOVA followed by a
Tukey–Kramer post hoc test of significance. n = 3 for each group.
Data are represented as mean ± SD.
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analog. All three analogs produce a statistically significant dose-
responsive reduction in proliferation that is remarkably similar in de-
gree (Figure 7B). Furthermore, this antiproliferation is nonsynergistic,
because combinatorial administration does not strengthen the effect
(data not shown).
In the same experiment, we compared expansion among cells treated
with either BrdU or one of two anticancer nucleosides, 5-FU or AZA.
Each analog was administered to H9 cells at 0, 1, 10, or 50 μM for
18 hours, and cells were quantified weekly for three consecutive weeks
(Figure 7C ). At 1 week, AZA-treated cells are not significantly dif-
ferent from controls, whereas both BrdU- and 5-FU–treated cells are
reduced by 50% to 60%. At 2 weeks, AZA-treated cells still match
control levels, whereas the BrdU and 5-FU groups have dropped to
approximately 10% of control. At week 3, the BrdU-treated cells
are maintained near 10% of control level, whereas the 5-FU treated
cells recover to approximately 35%. 5-Aza-2′-deoxycytidine showed
substantial variability, with some treated cells demonstrating a sta-
tistically significant reduction to approximately 80% of control, but
this reduction is not maintained over time (data not shown). These
results suggest that the suppressive effect of single-pulse BrdU on
cancer cell expansion is more effective than AZA and is more persistent
than 5-FU.
BrdUAdministration Slows Glioma Tumor Progression In Vivo
We chose a syngeneic, invasive, nonimmunogenic rat glioma model
[46–48] to test whether the proliferation suppression of BrdU has a
meaningful in vivo correlate. RG2 tumors are refractory to therapeutic
modalities, rendering them nearly impossible to treat efficiently or
cure. Their invasive pattern of growth and uniform lethality after an
inoculum of relatively few cells make them a particularly attractive
model to test new therapeutic modalities [49].
First, we injected a bolus of RG2 cells—either untreated or pre-
treated in vitro for 24 hours with 50 μM BrdU—subcutaneously into
Fisher 344 rats and followed tumor progression. All animals eventually
develop tumors, but the survival time (defined as 3000-mm3 tumor
volume) is dramatically delayed in animals receiving pretreated cells
(Figure 8A). This result clearly demonstrates that proliferation sup-
pression induced by in vitro application of BrdU is maintained in
the in vivo environment.
In a second set of experiments, we tested whether tumor progres-
sion can be slowed by in vivo administration of BrdU. Animals were
inoculated with naive RG2 cells and then treated with either i.p.
or oral BrdU. After implantation, one group of animals received
six i.p. injections of BrdU (300 mg/kg) over 2 days (Figure 8B),
while a second group was placed on ad libitum drinking water con-
taining 0.8 mg/ml BrdU for 1 week (Figure 8C ). In both cases, there
is a statistically significant increase in survival in the animals receiv-
ing BrdU, indicating that BrdU is effective at slowing the growth of
cancer cells in vivo even when it is administered after tumor initia-
tion. Even a modest increase in survival time after a conservative dos-
ing regimen is highly encouraging when one considers the refractory
nature of these tumors.
Discussion
Bromodeoxyuridine has a long history as a potential anticancer
drug, and it is known that at high doses and in combination with
secondary stressors, such as ionizing radiation, BrdU can have lethal
consequences for incorporating cells. The present findings are sur-
prising in that our BrdU regimen is exceedingly mild, even by cur-
rent experimental pulse-chase birth-dating paradigms in which cells
incorporate BrdU and continue to function in an apparently normal
manner. Furthermore, the suppressed proliferation we describe oc-
curs in the absence of secondary insults that would stress the cells
ability to maintain homeostasis or undergo DNA repair.
A role for BrdU in senescence induction of mammalian cells has
recently been described in the gerontology field [33], but this role is
not yet widely appreciated by the larger scientific community and has
Figure 8. BrdU administration slows tumor progression in a syn-
geneic in vivo glioma model. RG2 rat glioma cells, either untreated
or pretreated with 50 μM BrdU, were injected subcutaneously in
Fisher 344 rats. Tumor progression was monitored by taking mea-
surements every other day and calculating tumor volume. Animals
were euthanized when the tumor volume reached the critical end
point (3000 mm3). (A) Animals that received the RG2 glioma cells
that had been pretreated with 50 μM BrdU for 24 hours show a
significant delay in tumor progression when compared to the con-
trol animals (P = .002). (B) Animals that received subcutaneous
injections of untreated RG2 cells but were administered BrdU by
i.p. injections (300 mg/kg × 1.5 days) also show significant delays
in tumor progression (P = .02). Additionally, (C) animals that re-
ceived subcutaneous injections of untreated RG2 cells and were
administered BrdU in their drinking water (0.8 mg/ml for 7 days)
show a significant delay in tumor progression (P = .04). Kaplan–
Meier survival curves (χ 2 test with associated P value). n = 10 for
each group.
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not previously been applied as an approach to slow tumor progres-
sion. Emerging in vivo studies underscore the importance of cellular
senescence in altering the growth properties of tumors in humans
and rodents [49,50], and we show here that cancer cells treated with
single-pulse BrdU show some signs consistent with senescence. Both
the altered cell cycle profile and the up-regulation of SAβ-gal are
common manifestations of a senescent phenotype; however, SAβ-
gal up-regulation varies widely by cell line, with some showing no
enzyme activity even during severe suppression of proliferation rate,
and there is evidence suggesting that SAβ-gal is not necessarily a se-
lective marker of senescence [51]. It seems, then, that BrdU exposure
does not lead to classically defined “senescence” but to a generalized
slowing of proliferation and does not, in our experimental paradigm,
lead to crisis or subsequent cell death. Furthermore, the battery of
cell lines we have examined all show similar proliferation suppression
after BrdU exposure yet differ widely in the status of quintessential
senescence markers (Table W2). This variability makes it difficult to
define a “universal” mechanism of action and suggests that these mo-
lecular players, while possibly involved in a cell type–dependent
manner, are neither required nor causative for the suppressive effect
of BrdU. Our cell cycle data indicate that BrdU-treated cells accumu-
late in G1 suggesting that these cells either may exit the cell cycle
or are unable to traverse the restriction point. Although the control
of cellular proliferation is tightly regulated by various intrinsic and
extrinsic factors, pRb is generally regarded as the master regulator
of the restriction point and is now implicated in cellular senescence.
Retinoblastoma protein is believed to control a senescence-initiating
pathway that may synergize with, but is distinct from, telomere
loss [33,52]. Our results showing perturbed proliferation that
corresponds with hypo-/unphosphorylated pRb yet seems to be
independent of telomere maintenance supports this theory. The post-
administration times at which the levels of phosphorylated pRb
become undetectable in BrdU-treated RG2 and BJ cells almost per-
fectly correspond to the accumulation of these cells in G1. However,
results showing similar proliferation suppression in pRb null Saos-2
human osteosarcoma cells (data not shown) again indicates that pRb
is not required for BrdU’s effect.
Proliferation was suppressed in all of the cells that we examined,
and prior studies have also demonstrated the ubiquitous susceptibil-
ity of mammalian cells to BrdU [9]. There is even evidence that
BrdU slows replication in thymidine–auxotrophic yeast (unpublished
observation; [53]), suggesting that BrdU-mediated proliferation sup-
pression in all eukaryotic cells may be affected through a common yet
still undefined mechanism. Cancer stem cells seem particularly sus-
ceptible to the antiproliferative effect of BrdU. The NS-forming assay
allows us to study the behavior of stem cell–like tumor-initiating
cells, and a single pulse of BrdU reliably and dramatically slows
the proliferation of clonally expanded progeny over numerous pop-
ulation doublings. This result strongly suggests that BrdU may be a
potent therapeutic, targeting cancer stem cells and potentially slow-
ing the regrowth of debulked primary tumors and/or the metastatic
spread of secondary tumors. The wide penetrance of the antiproli-
ferative effect, combined with the ability for rapid transport across
the blood–brain barrier, makes BrdU an attractive candidate against
all types of cancer. However, these same attributes also make it likely
that indigenous stem cell pools will be adversely affected. Therefore,
potential therapeutic BrdU dosing regimens will need to be carefully
tested to avoid a permanent depletion of the stem cells and long-term
progenitors needed for maintaining tissue homeostasis.
We consider delayed in vivo tumor progression in the extremely
aggressive RG2 model to be the most important aspect of our study.
Glioblastoma multiforme is the most common primary (i.e., non-
metastatic) brain tumor of humans. Despite advances in cytoreduc-
tive and cytotoxic therapies, the prognosis for this neoplasm remains
dismal, with a median survival time of approximately 12 months
[54–56]. This has fostered an intense interest in the search for alter-
native therapeutic modalities that may prove to be more effective or
that may augment standard surgical, radiologic, or chemotherapeutic
treatments for these neoplasms [57]. The RG2 glioma model has
been posited as the equivalent of human glioblastoma multiforme.
The fact that brief administration times used in our study result in
statistically significant delays in the growth of naive tumor cells raises
the possibility that BrdU alone may be capable of producing biologi-
cally significant therapeutic gains under optimized dosing schedules.
In addition, the dramatically delayed progression of BrdU-pretreated
cells (treated before implantation) suggests that BrdU may prove ef-
fective against secondary metastatic tumor formation. Future studies
will be directed at examining the homing and invasiveness of BrdU-
incorporating cells and their progeny.
In reassessing BrdU as a potential anticancer drug, it is important
to ask why the clinical trials of BrdU as a radiosensitizer were rela-
tively ineffective at extending survival. Although these previous stud-
ies were concerned only with the extent to which BrdU augmented
the standard chemical and radiation therapies, one would expect that
the antiproliferative effect of BrdU should still have been evident.
On the basis of our present findings, we can offer reasonable specu-
lation as to why results from these earlier trials were so ambiguous.
First, these clinical studies were performed solely based on in vitro
evidence of BrdU radiosensitization [3,12,58]; thus, the study de-
signs did not have the benefit of in vivo models that may have
revealed dosing schedules and drug interaction effects that either op-
timize or attenuate BrdU incorporation. Second, in all of the clinical
trials, BrdU was added to an existing, multimodal therapy that in-
volved both chemotherapeutics and fractionated irradiation. Under
these circumstances, it is not clear to what extent BrdU was systemi-
cally available during stages of active tumor cell division. Related
to this is the question of dose and treatment length optimization;
without the benefit of animal models, it simply was not possible to
determine sufficient dosing schedules to maximize therapeutic out-
come. Even our present results with in vivo BrdU administration
do not necessarily represent an optimized treatment paradigm, as
we were intentionally conservative in our approach and were able
to elicit a therapeutic effect while staying well below side effect limi-
tations. It remains for future studies to extend these results to define
the most effective treatment regimen from a cost/benefit perspective.
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Table W1. Statistical Analyses for Results Presented in Figure 4.
Cell Line Time (h) Estimated R SD of Estimated R Z P Significance Using Bonferroni Correction
TT 0 1 0 N/A N/A
4.5 0.414 0.012 48.043 .0 *
H9 0 1.000 0.000 N/A N/A
1 0.921 0.055 1.426 .154
2 0.691 0.053 5.866 .000 *
4 0.636 0.018 19.737 .000 *
8 0.057 0.001 643.575 .000 *
BJ 0 1.000 0.000 N/A N/A
5 0.534 0.020 23.068 .000 *
9 0.434 0.028 20.375 .000 *
14 0.213 0.003 244.630 .000 *
RG2 0 1.000 0.000 N/A N/A
5 0.213 0.010 74.463 .000 *
7 0.114 0.001 831.531 .000 *
14 0.007 0.001 12735.210 .000 *
MG63 0 1.000 0.000 N/A N/A
3 0.631 0.042 8.693 .000 *
Figure W1. Expansion suppression is not due to BrdU-mediated
photolysis. Because BrdU has been shown to increase the sen-
sitivity of cells to irradiation, including light, we exposed MG63
human osteosarcoma cells to 50 μM BrdU for 24 hours and cul-
tured them under light protection for 5 days. Even under these
conditions, BrdU-treated cells expanded at a significantly slower
rate than controls (unpaired t test, Welch-corrected, P < .0001).
n = 3 for each group. Error bars represent SD.
Figure W2. BrdU induces a negligible increase in apoptotic cell death. (A) Apoptosis was assessed with the TUNEL assay in RG2 rat
glioma cells that received a 24-hour pulse of either 10 or 50 μM BrdU. At all time points, after BrdU exposure, treated groups show sig-
nificant increases in TUNEL+ cells compared to control. However, even the highest rate of apoptosis represents less the 0.5% of the
total cell number. (B) Cleaved caspase-3 was assessed in control (C ) and BrdU-treated (B) BJ and MG63 cells at 1, 6, 24, 72, and 96 hours
after a single 24-hour exposure to 50 μM BrdU. In none of the groups does the percentage of caspase-3+ cells exceed 1% of the total
population, and there are no consistent differences between treated and control groups in either cell line. (C) Annexin V labeling (purple)
shows a dose-responsive increase in MG63 cells exposed for 24 hours to 1, 10, or 50 μM BrdU. In addition, there is a slight increase in
dead cells (green) with increasing concentration of BrdU. (D) Annexin V labeling was assessed in control (C ) and treated (B) H9, Saos-2,
and BJ cells at various times after a single 24-hour exposure to 50 μM BrdU. H9, but not Saos-2 or BJ cells show an increase in Annexin
V label (purple) by treated cells. Additionally, untreated control cells show wide variability in the constitutive level of Annexin V labeling,
with approximately 50% of control BJ cells labeled positive.
Figure W3. BrdU does not perturb mitochondrial membrane physiology. MG63 human osteosarcoma cells received a 24-hour pulse of
50 μM BrdU, and mitochondrial membrane physiology was assessed using the JC-1 potentiometric dye. Mitochondrial membrane de-
polarization is indicated by a decrease in the red/green fluorescence intensity ratio. (A) Control MG63 cells were treated with CCCP (a
mitochondrial membrane disrupter) as a positive control for depolarization. At both 24 hours (B and C) and 7 days (D and E) after BrdU
exposure, control and treated cells display equivalent membrane potentials.
Table W2. Reported Statuses of Prominent Senescence-Related Markers for All Cell Lines Tested.
Cell Line Description p53 p16 p21 pRb Telomerase
H9 Human lymphoma Mutant −/− Not expressed Normal Positive
RG2 Rat glioma −/− −/− Normal N/A Positive
MG63 Human osteosarcoma −/− −/− Normal Normal Positive
BJ Human immortalized
fibroblasts
Normal Normal Normal Normal Negative
Saos-2 Human osteosarcoma −/− Normal Not expressed −/− Negative
TT Human thyroid cancer Mutant N/A N/A N/A Positive
Figure W4. BrdU induces an increase in SAβ-gal activity. RG2 rat
glioma cells treated with 50 μM BrdU for 24 hours show an in-
crease in the percentage of SAβ-gal+ cells within 24 hours. Error
bars represent SD.
Figure W5. BrdU has varying effects on telomerase expression but
does not alter telomere length. (A) RG2 rat glioma and MG63
human osteosarcoma cells were assayed for telomerase expres-
sion using TRAP analysis after a 24-hour pulse of 50 μM BrdU.
RG2 cells show a dramatic and statistically significant reduction
(P < .001 at 24 and 48 hours) in telomerase activity within 24 hours
of BrdU exposure, whereas telomerase in treated MG63 cells does
not vary from control levels even at 7 or 21 days after BrdU when
proliferation is severely suppressed. (B) Telomeric terminal restric-
tion fragment was performed on H9 human lymphoma cells 7 days
after a 24-hour pulse of 50 μM BrdU. There is no discernible differ-
ence in telomere length between the control and BrdU-treated cells.
